Abionyx Pharma SA
PAR:ABNX
Abionyx Pharma SA
PAR:ABNX
Price:
3.37
EUR
-0.88%
Market Closed
Market Cap:
€119.7m
Income Statement
Earnings Waterfall
Abionyx Pharma SA
Abionyx Pharma SA
Income Statement
Abionyx Pharma SA
Abionyx Pharma SA
Currency: EUR
| Dec-2015 | Jun-2016 | Dec-2016 | Jun-2017 | Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
-2%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
+2 400%
|
3
+386%
|
5
+60%
|
5
-10%
|
5
-2%
|
5
+5%
|
5
-6%
|
4
-5%
|
|
| Gross Profit | |||||||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(3)
|
(5)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+25%
|
1
+96%
|
1
-16%
|
1
+16%
|
1
+51%
|
1
-9%
|
1
-9%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(15)
|
(23)
|
(24)
|
(13)
|
(7)
|
(7)
|
(7)
|
(6)
|
(3)
|
(2)
|
(3)
|
(5)
|
(6)
|
(6)
|
(5)
|
(4)
|
(4)
|
(4)
|
(5)
|
(5)
|
|
| Selling, General & Administrative |
(3)
|
(6)
|
(7)
|
(4)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(2)
|
(3)
|
(4)
|
(3)
|
(3)
|
(3)
|
(3)
|
(4)
|
|
| Research & Development |
(13)
|
(18)
|
(17)
|
(9)
|
(5)
|
(5)
|
(5)
|
(3)
|
(1)
|
(1)
|
(2)
|
(4)
|
(6)
|
(5)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
(0)
|
(1)
|
(1)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
1
|
1
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Operating Income |
(15)
N/A
|
(23)
-50%
|
(24)
-4%
|
(13)
+46%
|
(7)
+48%
|
(7)
-1%
|
(7)
-5%
|
(6)
+22%
|
(3)
+54%
|
(2)
+16%
|
(3)
-40%
|
(5)
-52%
|
(6)
-32%
|
(6)
+2%
|
(4)
+29%
|
(4)
+6%
|
(3)
+12%
|
(3)
+3%
|
(4)
-35%
|
(5)
-5%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
1
|
0
|
2
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(1)
|
(1)
|
(1)
|
2
|
0
|
(1)
|
1
|
6
|
4
|
(0)
|
1
|
1
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
|
| Pre-Tax Income |
(17)
N/A
|
(24)
-46%
|
(25)
-3%
|
(11)
+56%
|
(5)
+54%
|
(8)
-54%
|
(6)
+18%
|
0
N/A
|
2
+710%
|
(2)
N/A
|
(2)
+13%
|
(4)
-86%
|
(6)
-66%
|
(6)
0%
|
(4)
+28%
|
(4)
+7%
|
(4)
+10%
|
(3)
+5%
|
(4)
-30%
|
(5)
-5%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
|
| Income from Continuing Operations |
(17)
|
(24)
|
(25)
|
(11)
|
(5)
|
(8)
|
(6)
|
(0)
|
2
|
(2)
|
(2)
|
(4)
|
(6)
|
(6)
|
(4)
|
(4)
|
(4)
|
(3)
|
(4)
|
(5)
|
|
| Net Income (Common) |
(17)
N/A
|
(24)
-46%
|
(25)
-3%
|
(11)
+56%
|
(5)
+54%
|
(8)
-54%
|
(6)
+18%
|
(0)
+100%
|
2
N/A
|
(2)
N/A
|
(2)
+4%
|
(4)
-86%
|
(6)
-66%
|
(6)
0%
|
(4)
+28%
|
(4)
+7%
|
(4)
+10%
|
(3)
+5%
|
(4)
-30%
|
(5)
-5%
|
|
| EPS (Diluted) |
-1
N/A
|
-1.36
-36%
|
-1.39
-2%
|
-0.61
+56%
|
-0.27
+56%
|
-0.42
-56%
|
-0.34
+19%
|
0
N/A
|
0.09
N/A
|
-0.09
N/A
|
-0.08
+11%
|
-0.15
-87%
|
-0.23
-53%
|
-0.22
+4%
|
-0.15
+32%
|
-0.14
+7%
|
-0.12
+14%
|
-0.11
+8%
|
-0.13
-18%
|
-0.14
-8%
|
|
Switch to:
Switch to:
See Also
Discover More
